Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.78 |
| ▸ | ASF1A | Q9Y294 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 3/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1930791 | 0.86 | MCHR1 (0.65) | MCHR1ASF1AKDREGFRMEN1 | |
| SCHEMBL6925669 | 0.83 | MCHR1 (0.93) | MCHR1ASF1AKDREGFRHTR2C | |
| SCHEMBL4256379 | 0.80 | NPC1 (0.76) | ABCB1MEN1KMT2AMAPT | |
| SCHEMBL14618438 | 0.80 | MCHR1 (0.79) | MCHR1ASF1AKDRHTR2AHTR2C | |
| SCHEMBL7056752 | 0.79 | MCHR1 (0.52) | MCHR1HTR2C | |
| SCHEMBL2323789 | 0.79 | LTA4H (0.66) | MCHR1HTR2AHTR2CMEN1KMT2A | |
| SCHEMBL14618441 | 0.79 | MCHR1 (0.77) | MCHR1ASF1AHTR2AHTR2CBCHE | |
| SCHEMBL6174157 | 0.79 | MCHR1 (0.62) | MCHR1ASF1AMEN1KMT2AMAPT | |
| SCHEMBL17560532 | 0.78 | MCHR1 (0.64) | MCHR1ASF1AHTR2AHTR2CBCHE | |
| SCHEMBL6477726 | 0.78 | MCHR1 (0.65) | MCHR1ASF1AKDRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | CNR1, GPR3, CCKAR | MCHR1 133/4885ASF1A 4311/4885KDR 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.